A Single-centre, Randomised, Double-blind, Multiple-dose, Placebo-controlled, Parallel-group Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 19 May 2017 Results published in the Diabetologia
- 16 Sep 2016 Results assessing effect of semaglutide on beta cell function presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 12 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.